SEARCH

SEARCH BY CITATION

References

  • 1
    Lau GKK. Hepatitis B infection in China. In: Clinics in Liver Disease 2001; 5: 36179.
  • 2
    Wong D, Cheung R, O'Rourke K, Naylor C, Detsky A, Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1991; 114: 62934.
  • 3
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40 kD) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg positive chronic hepatitis B: results from a large, multinational study. N Eng J Med 2005; 352: 268295.
  • 4
    Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365, 1239.
  • 5
    Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002; 36: 7029.
  • 6
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 6969.
  • 7
    Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 8139.
  • 8
    Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with hematological malignancy upon completion of cytotoxic chemotherapy. Gut 2005; 154: 1597603.
  • 9
    Lau GK, Cooksley H, Ribeiro RM, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology 2004; 38: 272A.
  • 10
    Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195202.
  • 11
    Pegintron. Peginterferon Alfa-2b. Product Monograph. Kenilworth, NJ: Schering-Plough Corporation, 2001.
  • 12
    Hui CK, Lau GKK. Peginterferon alfa-2a (40 kD) (Pegasys) for hepatitis B. Expert Review of Anti-Infective Therapy 2005; 3: 495504.
  • 13
    Cooksley WG, Piratvisuth T, Lee SD, et al. Peinterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hep 2003; 10: 298305.
  • 14
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Eng J Med 1998; 339: 6168.
  • 15
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Eng J Med 1999; 341: 125663.
  • 16
    Marcellin P, Lau G, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Eng J Med 2004; 351, 120617.
  • 17
    Chan LY, Leung N, Hui AY, et al. A randomized controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 24050.
  • 18
    Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Therap 2004; 20: 82530.
  • 19
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 20
    Zaman A, Fennerty MB, Keefe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003; 18: 66170.
  • 21
    Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 23843.
  • 22
    Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: results of a phase III study ETV-022 in nucleoside analogue-naïve patients. Hepatology 2004; 40(Suppl. 1): 193A.
  • 23
    Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 52836.
  • 24
    Yeoh EK, Chang WK, Kwan JPW. Epidemiology of viral hepatitis B infection in Hong Kong. In: LamSK, LaiCL, YeohEK, eds. Viral Hepatitis in the Western Pacific Region: Vaccine and Control. Singapore: World Scientific, 1984: 3344.
  • 25
    Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003; 39: 11524.
  • 26
    Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant alpha-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298302.
  • 27
    Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 20917.